Liver protective marc variants and uses thereof
AssigneeThe General Hospital Corporation
InventorsSekar Kathiresan, Connor Emdin
Life of this patent
Estimating the term…
Abstract
Described herein are MARC variants that associate with a risk of liver diseases or a symptom(s) thereof, such as cirrhosis, or protection against such liver diseases or symptom(s) thereof. Also described herein are compositions and formulations that can be capable of modulating MARC in a subject and/or treatment of a liver disease or a symptom thereof.
Claims20
A method of treating or preventing a liver disease or a symptom thereof in a subject in need thereof comprising:
- detecting a MARC1 risk allele, a MARC2 risk allele, or both in the subject in need thereof, wherein the presence of a MARC1 risk allele, a MARC2 risk allele, or both indicates that the subject in need thereof has an increased risk of liver disease;
- and
- administering, to the subject in need thereof, an amount of a treatment or preventative effective to reduce the amount of, activity of, or both of MARC1, MARC2, or both in the subject in need thereof.
A method of reducing total cholesterol, low-density lipoprotein, or a combination thereof in a subject in need thereof, comprising:
- administering, to the subject in need thereof, an amount of a treatment effective to reduce the amount of, activity of, or both of MARC1, MARC2, or both in the subject in need thereof.
An agent effective to reduce an amount of, activity of, or both of MARC1, MARC2, or both or effective to treat a liver disease or a symptom thereof, or both, comprising:
- comprises a MARC1-specific RNAi molecule, a MARC2-specific RNAi molecule, a small molecule agent, a MARC1-specific gene modifying agent, a MARC2-specific gene modifying agent, or a combination thereof,
- wherein the agent is produced by a method comprising
- administering an amount of a test agent to a subject;
- and
- determining
- a) the level or modulation thereof of a MARC1 in the subject;
- b) the level or modulation thereof of a MARC2 in the subject;
- c) the level of alanine transaminase (ALT) in the plasma of the subject;
- d) the level of aspartate transaminase (AST) in the plasma of the subject;
- e) the level of alkaline phosphatase (ALP) in the plasma of the subject;
- f) the level of the total cholesterol in the subject;
- g) the level of low-density lipoprotein (LDL) cholesterol in the subject;
- h) the level of high-density lipoprotein (HDL) cholesterol in the subject;
- i) the level of triglycerides in the subject;
- or
- j) a combination thereof,
- wherein the agent effective to reduce an amount of, activity of, or both of MARC1, MARC2, or both or effective to treat a liver disease or a symptom thereof, or both, is effective to
- a) reduce the amount, activity, or both of the MARC1 in the subject;
- b) reduce the amount, activity, or both of the MARC2 in the subject;
- c) reduce the level of ALT in the plasma of the subject;
- d) reduce the level of AST in the plasma of the subject;
- e) reduce the level of ALP in the plasma of the subject;
- f) reduce the level of total cholesterol in the subject;
- g) reduce the level of LDL cholesterol in the subject;
- h) reduce the level of HDL cholesterol in the subject;
- i) reduce the level of triglycerides in the subject;
- or
- j) any combination thereof.
Dependencies are inferred from the claim text.